drugset

drugset / Trial / NCT01201915

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

NCT01201915 ↗

Phase 2 Completed 74 enrolled Genentech, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.

Timeline

Start: 2010-10
Primary completion: 2013-05
Completion: 2013-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vismodegib	Small molecule	150 mg	Oral

Indications